# OnCo record n0147 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/n0147/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "n0147", "NCT00079274" ;
  schema:name "Alliance N0147"@en ;
  schema:alternateName "NCCTG N0147"@en ;
  schema:description "The North American version of the same question, with the same answer: cetuximab after surgery adds toxicity and no benefit."@en ;
  schema:url <https://onco.cc/trials/n0147/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00079274>, <https://doi.org/10.1001/jama.2012.385> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/irinotecan/> ;
  onco:companies <https://onco.cc/companies/alliance-oncology/> ;
  onco:trials <https://onco.cc/trials/petacc-8/>, <https://onco.cc/trials/atomic/> .